Linezolid Resistance in Staphylococcus aureus : Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances

Linezolid Resistance in Staphylococcus aureus : Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances Elevated Linezolid Resistance in Clinical cfr -Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3 Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center Activity of Linezolid in anIn VitroPharmacokinetic-Pharmacodynamic Model Using Different Dosages andStaphylococcus aureusandEnterococcus faecalisStrains with and without a Hypermutator Phenotype Delayed Development of Linezolid Resistance in Staphylococcus aureus following Exposure to Low Levels of Antimicrobial Agents Mutations in Ribosomal Protein L3 Are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States Mutations in 23S rRNA at the Peptidyl Transferase Center and Their Relationship to Linezolid Binding and Cross-Resistance Resistance Selection Studies Comparing the Activity of Razupenem (PTZ601) to Vancomycin and Linezolid against Eight Methicillin-Resistant and Two Methicillin-Susceptible Staphylococcus aureus Strains Resistance to Linezolid in a Porcine Clostridium perfringens Strain Carrying a Mutation in the rplD Gene Encoding the Ribosomal Protein L4